Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | BLM | P54132 | 2/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GMNN | O75496 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11938132 | 0.97 | KMT2A (0.50) | KMT2ALMNAHSD17B10TDP1ALOX15 | |
| SCHEMBL1106831 | 0.89 | — | — | |
| SCHEMBL10024581 | 0.89 | — | — | |
| SCHEMBL1106829 | 0.89 | LMNA (0.74) | KMT2ALMNAHSD17B10TDP1ALOX15 | |
| SCHEMBL15147841 | 0.88 | KMT2A (0.41) | KMT2ALMNAHSD17B10TDP1ALOX15 | |
| SCHEMBL24169230 | 0.87 | — | — | |
| SCHEMBL9162190 | 0.87 | — | — | |
| SCHEMBL4858666 | 0.84 | TDP1 (0.40) | KMT2ALMNAHSD17B10TDP1ALOX15 | |
| SCHEMBL3068716 | 0.84 | TSHR (0.44) | KMT2ALMNAHSD17B10TDP1ALOX15 | |
| SCHEMBL11713291 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108882704-B | Molecules having pesticidal utility, and intermediates, compositions and methods related to these molecules | 美国陶氏益农公司 | 2021-09-10 | — | — | CN | claimed |
| US-4306048-A | Method for preparing acrylamide polymers | NITTO CHEMICAL INDUSTRY CO., LTD. (JP) | 1981-12-15 | — | — | US | claimed |
| EP-4400492-A1 | ACRIDINE COMPOUND | OSAKA UNIVERSITY (JP) | 2024-07-17 | — | — | EP | disclosed |
| US-20240208999-A1 | HETEROCYCLIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-06-27 | — | — | US | disclosed |
| EP-4370507-A1 | HYDROGENATED QUINOXALINES | Otsuka Pharmaceutical Co., Ltd. (JP) | 2024-05-22 | — | — | EP | disclosed |
| CN-117940408-A | Acridine compounds | 国立大学法人大阪大学 | 2024-04-26 | — | — | CN | disclosed |
| EP-4347597-A1 | PYRAZOLO[1,5-A]PYRIMIDINE COMPOUND FOR THE TREATMENT OF DERMAL DISORDERS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2024-04-10 | — | — | EP | disclosed |
| US-20240109842-A1 | ACRYLAMIDE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-04-04 | — | — | US | disclosed |
| US-11932657-B2 | Heterocyclic compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-03-19 | — | — | US | disclosed |
| CN-117616013-A | Hydrogenated quinoxalines | 大塚制药株式会社 | 2024-02-27 | — | — | CN | disclosed |
| CN-117377674-A | Pyrazolo [1,5-a ] pyrimidine compounds for the treatment of dermatological disorders | 大塚制药株式会社 | 2024-01-09 | — | — | CN | disclosed |
| WO-2003060192-A1 | NON-TOXIC CORROSION-PROTECTION RINSES AND SEALS BASED ON COBALT | UNIVERSITY OF DAYTON (US) | 2003-07-24 | — | — | WO | disclosed |
| EP-0407123-B1 | Films for packaged articles eliminating air entrapment | DU PONT (US) | 1996-10-09 | — | — | EP | disclosed |
| EP-0475160-B1 | Preparation for drug application in minute droplet form | IDEA AG (DE) | 1996-02-14 | — | — | EP | disclosed |
| US-5162154-A | Packaging smooth-surfaced article with transparent film having surface of a polymer which in film form exhibits specular gloss of at least 20, measured at angle of 20 degrees, and synthetic amorphous silica of 0.5-50 micrometer particle size | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-11-10 | — | — | US | disclosed |
| EP-0407123-A2 | Films for packaged articles eliminating air entrapment | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-01-09 | — | — | EP | disclosed |
| US-4569766-A | MALEIMIDES | THE STANDARD OIL COMPANY (US) | 1986-02-11 | — | — | US | disclosed |
| US-4306048-A | Method for preparing acrylamide polymers | NITTO CHEMICAL INDUSTRY CO., LTD. (JP) | 1981-12-15 | — | — | US | disclosed |
| US-4243762-A | Alkanolamine processing aid for ethylene-vinyl ester interpolymer particles present in aqueous dispersions thereof | NATIONAL DISTILLERS AND CHEMICAL CORP. (US) | 1981-01-06 | — | — | US | disclosed |
| US-4105763-A | 1-Methyl-2-(phenyl-oxymethyl)-5-nitro-imidazoles | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109842-A1 | ACRYLAMIDE COMPOUNDS | HPGDS, MYADM, ACR | KMT2A 2079/4885LMNA 1924/4885HSD17B10 2917/4885 |
| US-11932657-B2 | Heterocyclic compound | AHR, PDGFRA, PDGFRB | KMT2A 1736/4885LMNA 3284/4885HSD17B10 691/4885 |
| US-20240208999-A1 | HETEROCYCLIC COMPOUND | AHR, PDGFRA, PDGFRB | KMT2A 1736/4885LMNA 3284/4885HSD17B10 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.